Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month
- Migraine Impact Report highlights physical, social and economic challenges of migraine -
- Respondents diagnosed with migraine experienced on average 15.4 completely pain-free days over previous 30 days -
INDIANAPOLIS, February 20, 2018 – Eli Lilly and Company (NYSE:LLY) announced today findings from a Lilly-sponsored, quantitative opinion survey, which found among those surveyed, people diagnosed with migraine experienced on average 15.4 completely pain-free days over the previous 30 days. The Migraine Impact Report also highlighted the impact of migraine on a person’s day-to-day-life, with respondents noting the symptoms of their migraine prevented them from doing what they wanted to do for one week (6.9 days) over the previous 30 days.
The Migraine Impact Report evaluated the physical, social and economic challenges of migraine. Respondents included 1,018 U.S. adults, including 518 people who have been diagnosed with migraine by a healthcare provider, 200 people who know someone with migraine and 300 community members who do not know someone with migraine.
Notably, the worst migraine pain ranked higher than that of childbirth among those surveyed who had experienced both (n=244, an average score of 8.6 compared to 7.3, on a scale of one to 10). Respondents diagnosed with migraine on average rated the worst migraine pain similarly to that of the “most painful thing I have ever experienced” (8.6 compared to 8.7), and higher than both the pain associated with kidney stones and broken bones (8.3 and 7.0, respectively).
“As a practicing neurologist, I saw firsthand both the burden faced by people living with this often disabling, neurological disease, and the feeling that people must ‘power through’ their lives because those around them may not understand just how all-encompassing migraine can be,” said Sheena Aurora, M.D., medical fellow, Eli Lilly and Company.
People who do not have migraine often underestimate the pain and average duration of migraine.
- Nearly all respondents diagnosed with migraine (91 percent) agreed those who do not suffer from migraine do not understand the severity of the disease.
- 62 percent of those surveyed who were diagnosed with migraine agreed they try to hide the true impact of migraine from those at work or at school.
- On a scale of one to 10, those surveyed who did not know someone with migraine underestimated the pain of a typical migraine (an average score of 6.2 compared to an average score of 7.1 given by people diagnosed with migraine).
- On average, respondents diagnosed with migraine estimated the length of a migraine as 10.3 hours longer than those respondents who do not have migraine (an average score of 31 hours per migraine compared to an average score of 20.7 hours per migraine, respectively).
Migraine frequently adds stress and may result in less time with family.
- Among those diagnosed with migraine, 82 percent of survey respondents agreed it is stressful to have an unpredictable disease like migraine.
- Respondents diagnosed with migraine missed an average of 7.4 important events in the previous year due to migraine, such as birthdays, graduations or holiday gatherings.
- Nearly three-quarters of respondents diagnosed with migraine (70 percent) agreed with the statement, “I’ve avoided making plans because of migraine.”
- Nearly three out of four parents surveyed who were diagnosed with migraine (72 percent) agreed migraine affects their ability to take care of their family.
- Among those surveyed with children under 13 years of age, 77 percent of people diagnosed with migraine agreed they were not able to interact as much with their children as they wanted.
Migraine may impact a person’s career potential.
- Among employed respondents diagnosed with migraine, seven out of 10 (68 percent) agreed they have been less productive at work due to migraine.
- More than half of respondents diagnosed with migraine (55 percent) agreed the disease has affected their career goals, and one in three respondents diagnosed with migraine (32 percent) agreed they have turned down opportunities at work because of migraine, including a promotion.
- More than one-third of respondents diagnosed with migraine agreed they have missed out on opportunities at work (39 percent) or additional earnings potential (38 percent) because of migraine.
Most respondents diagnosed with migraine agreed they wish they could do more to manage their disease.
- 81 percent of respondents diagnosed with migraine agreed they wish they could do more to manage their disease, while more than half of those diagnosed with migraine (54 percent) agreed no matter how hard they try, they don’t feel they can manage migraine.
- Notably, nearly all those surveyed who have a family member with migraine (90 percent) agreed they feel “helpless” when their loved one has a migraine.
- Among those who have a close relationship with someone with migraine, three out of four respondents (74 percent) agreed they would like this person to seek better care or treatment for their migraine.
“Results from the Migraine Impact Report support what physicians who care for patients with migraine have known for many years. The results also demonstrate the severity of this disease and the pervasive impact migraine has on an individual’s personal, family and professional life,” said Dr. Timothy R. Smith, MD, RPh, FACP, Vice President, National Headache Foundation. “These findings shine a spotlight on the serious need for additional treatment options for the more than 36 million Americans battling with migraine, many of whom lack a treatment option that addresses their symptoms and allows them to function in their day-to-day lives or which is tolerable for them.”
For more information about migraine and resources available for patients, such as finding a doctor in your area, visit the National Headache Foundation website at www.headaches.org.
About the Migraine Impact Report
The Migraine Impact Report is a 15-minute, online, quantitative opinion survey conducted by Nielsen on behalf of Eli Lilly and Company in May 2017. The survey was completed by 1,018 U.S. adults, including 518 people who have been diagnosed with migraine by a healthcare provider, 200 people who know a family member with migraine and 300 community members who do not know someone with migraine. Data for both people diagnosed with migraine and the general population were weighted to ensure representation from each group. Survey respondents were not restricted based on frequency or severity of migraine.
Migraine is a disabling neurological disease characterized by recurrent episodes of severe headache, and is often accompanied by other symptoms including nausea, vomiting, sensitivity to light and sound, and changes in vision.1,2 More than 36 million Americans have migraine, with three times more women affected by migraine compared to men.3,4 Of the approximately 40 percent of patients suffering from migraine for whom prevention is appropriate, only 12 percent are currently receiving therapy.5,6,7 Results from the Second International Burden of Migraine study show that side effects of treatment play a role in this disconnect, with up to 54 percent of respondents discontinuing migraine prevention therapy because of side effects.8 According to the Migraine Research Foundation, healthcare and lost productivity costs associated with migraine are estimated to be as high as $36 billion annually in the United States, yet it remains under-recognized and under-treated.4,7
About Lilly in Migraine
Lilly has been committed to helping people suffering from migraine for over 25 years, investigating more than a dozen different compounds for the treatment of headache disorders. These research programs have accelerated understanding of this disease and advanced the development of Lilly’s comprehensive late-stage development programs studying potential treatments for the acute and preventive treatment of migraine. Our goal is to make life better for people with migraine by offering comprehensive solutions to prevent or stop this disabling disease. The combined clinical, academic and professional experience of our experts helps us to build our research portfolio, identify challenges for healthcare providers and pinpoint the needs of patients living with migraine and cluster headache.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels.
1 Headache disorders. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs277/en/. Accessed December 4, 2017.
2 Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual Review of Pharmacology and Toxicology. 2015;55:533-552.
3 Living with migraine. American Migraine Foundation website. https://americanmigrainefoundation.org/living-with-migraines/. Accessed December 4, 2017.
4 Migraine facts. Migraine Research Foundation website. http://migraineresearchfoundation.org/about-migraine/migraine-facts/. Accessed December 4, 2017.
5 Lipton RB, Bigal ME, Diamond M, et al.; for the aMPP Advisory Group. Migraine prevalence, disease burden and the need for preventive therapy. Neurology. 2007;68(5):343-349.
6 Lafata, JE, Tuniceli O, Cerghet M, et al. The use of migraine preventive medications among patients with and without migraine headaches. Cephalalgia. 2010;30(1):97-104.
7 Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Prevalence and Prevention study. Headache. 2007;47(3):355-363.
8 Katic B, Rajagopalan S, Ho TW, et al. Triptan persistency among newly initiated users in a pharmacy claims database. Cephalalgia. 2011;31(4):488-500.